General Information of Drug Combination (ID: DCC63N1)

Drug Combination Name
Rifabutin Bedaquiline
Indication
Disease Entry Status REF
Tuberculosis, Pulmonary Phase 2 [1]
Component Drugs Rifabutin   DM1YBHK Bedaquiline   DM3906J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rifabutin
Disease Entry ICD 11 Status REF
Mycobacterium infection 1B10-1B21 Approved [2]
Tuberculosis 1B10-1B14 Approved [2]
Rifabutin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA-directed RNA polymerase (RNAP) TTHKJLN NOUNIPROTAC Modulator [5]
------------------------------------------------------------------------------------
Rifabutin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Bedaquiline
Disease Entry ICD 11 Status REF
Drug-resistant tuberculosis N.A. Approved [3]
Multi-drug resistant tuberculosis MG52.00 Approved [4]
Pulmonary tuberculosis 1B10.Z Approved [3]
Bedaquiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Proton pump (MycB Prop) TT19K0L A0A1Q4HQH4_9MYCO Modulator [7]
------------------------------------------------------------------------------------
Bedaquiline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Tuberculosis DCQ2NGW N. A. Phase 1 [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05766267) Short-course Regimens for the Treatment of Pulmonary Tuberculosis
2 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3 Bedaquiline FDA Label
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
9 ClinicalTrials.gov (NCT01341184) TMC207 +/- Rifabutin/Rifampin